← Back to Screener
Sangamo Therapeutics, Inc. Common Stock (SGMO)
Price$0.27
Favorite Metrics
Price vs S&P 500 (26W)-66.90%
Price vs S&P 500 (4W)-27.51%
Market Capitalization$111.90M
All Metrics
Book Value / Share (Quarterly)$0.02
P/TBV (Annual)9.35x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-29.17%
Cash Flow / Share (Quarterly)$-0.28
Price vs S&P 500 (YTD)-39.62%
Net Profit Margin (TTM)-310.81%
EPS (TTM)$-0.44
10-Day Avg Trading Volume5.26M
EPS Excl Extra (TTM)$-0.44
Revenue Growth (5Y)-19.66%
EPS (Annual)$-0.44
ROI (Annual)-430.13%
Net Profit Margin (5Y Avg)-192.08%
Cash / Share (Quarterly)$0.06
Revenue Growth QoQ (YoY)88.43%
ROA (Last FY)-205.76%
Revenue Growth TTM (YoY)-31.57%
EBITD / Share (TTM)$-0.43
ROE (5Y Avg)-175.64%
Operating Margin (TTM)-306.53%
Cash Flow / Share (Annual)$-0.28
P/B Ratio17.92x
P/B Ratio (Quarterly)32.54x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)2.30x
Net Interest Coverage (TTM)-222.00x
ROA (TTM)-148.06%
EPS Incl Extra (Annual)$-0.44
Current Ratio (Annual)0.84x
Quick Ratio (Quarterly)0.74x
3-Month Avg Trading Volume5.99M
52-Week Price Return-61.72%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.11
P/S Ratio (Annual)2.83x
Asset Turnover (Annual)0.66x
52-Week High$0.84
Operating Margin (5Y Avg)-197.67%
EPS Excl Extra (Annual)$-0.44
CapEx CAGR (5Y)-63.00%
Tangible BV CAGR (5Y)-43.03%
26-Week Price Return-60.01%
Quick Ratio (Annual)0.74x
13-Week Price Return-37.19%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.84x
Enterprise Value$90.947
Revenue / Share Growth (5Y)-30.64%
Asset Turnover (TTM)0.48x
Book Value / Share Growth (5Y)-50.84%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-312.25%
Cash / Share (Annual)$0.06
3-Month Return Std Dev140.04%
Net Income / Employee (TTM)$-1
ROE (Last FY)-430.13%
EPS Basic Excl Extra (Annual)$-0.44
P/FCF (TTM)9.61x
Receivables Turnover (TTM)88.19x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.44
Receivables Turnover (Annual)88.19x
ROI (TTM)-813.95%
P/S Ratio (TTM)2.83x
Pretax Margin (5Y Avg)-192.86%
Revenue / Share (Annual)$0.14
Tangible BV / Share (Annual)$0.11
Price vs S&P 500 (52W)-96.35%
Year-to-Date Return-35.69%
5-Day Price Return5.59%
EPS Normalized (Annual)$-0.44
ROA (5Y Avg)-103.40%
Net Profit Margin (Annual)-310.81%
Month-to-Date Return9.40%
Cash Flow / Share (TTM)$-1.36
EBITD / Share (Annual)$-0.43
Operating Margin (Annual)-306.53%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-175.64%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.44
P/TBV (Quarterly)9.35x
P/B Ratio (Annual)9.35x
Pretax Margin (TTM)-312.25%
Book Value / Share (Annual)$0.11
Price vs S&P 500 (13W)-39.57%
Beta1.55x
P/FCF (Annual)0.72x
Revenue / Share (TTM)$0.12
ROE (TTM)-813.95%
52-Week Low$0.20
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.92
4.00
4.00
4.00
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SGMOSangamo Therapeutics, Inc. Common Stock | 2.83x | -31.57% | — | — | $0.27 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Sangamo Therapeutics is a genomic medicine company developing gene-based therapies for serious genetic and neurological diseases. Its pipeline includes programs in neurology (chronic neuropathic pain, prion disease, ALS, FTD, Huntington's disease), hematology (hemophilia A), and other indications including Fabry disease and multiple sclerosis, with several programs advanced through partnerships.